Actinium Unveils Actimab-A and Menin Inhibitors Combo Data Showing Anti-Tumor Effects in Leukemia at 2024 EHA Congress

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a pioneer in Antibody Radiation Conjugates (ARCs) and targeted radiotherapies, has unveiled the first preclinical data on the combination of menin inhibitors with Actimab-A for treating acute myeloid leukemia (AML). The findings were disclosed at the 2024 European Hematology Association (EHA) Congress, held from June 13 to 16 in Madrid, Spain.

Researchers at Actinium explored the efficacy of Actimab-A when used alongside leading menin inhibitors, specifically revumenib from Syndax Pharmaceuticals, Inc. and ziftomenib from Kura Oncology, Inc. These menin inhibitors are being developed for AML patients with KMT2A rearrangements and NMP1 mutations, which are found in about 10% and 30% of AML cases, respectively.

According to the preclinical studies, the combination therapy of Actimab-A and menin inhibitors demonstrated a remarkable dose-dependent increase in cell death in KMT2A-sensitive AML cells. The results showed that the combined treatment achieved significant tumor eradication, a milestone not reached by using either treatment as a monotherapy. This discovery highlights the potential of menin inhibitors to enhance the therapeutic effects of Actimab-A.

The preclinical data presented at the EHA Congress suggest that combining menin inhibitors with Actimab-A could extend the drug’s efficacy as a treatment backbone for AML. Actimab-A has already shown effectiveness when combined with traditional chemotherapy, venetoclax, and FLT3 inhibitors, and the addition of menin inhibitors could further improve patient outcomes.

In summary, Actinium Pharmaceuticals has presented groundbreaking preclinical data indicating that the combination of Actimab-A and menin inhibitors could offer a more effective treatment strategy for AML patients, particularly those with specific genetic mutations like KMT2A rearrangements and NMP1 mutations. This combination therapy has the potential to achieve greater tumor elimination and enhance survival rates compared to current monotherapy treatments.